Hemorrhagic events
. | Pre-ULR group*(%) . | Post-ULR group*(%) . | P† . |
---|---|---|---|
Overall‡q | 44/315 (14) | 38/302 (13) | .70 |
Platelet refractory | 27/127 (21) | 18/68 (27) | .52 |
Alloimmunized | 14/61 (23) | 3/21 (14) | .59 |
Alloimmune refractory | 11/44 (25) | 2/12 (17) | .83 |
. | Pre-ULR group*(%) . | Post-ULR group*(%) . | P† . |
---|---|---|---|
Overall‡q | 44/315 (14) | 38/302 (13) | .70 |
Platelet refractory | 27/127 (21) | 18/68 (27) | .52 |
Alloimmunized | 14/61 (23) | 3/21 (14) | .59 |
Alloimmune refractory | 11/44 (25) | 2/12 (17) | .83 |